TJ Cradick Bio
TJ Cradick, PhD, is a CRISPR and Gene Editing expert with > 22 years of research and management experience.
TJ Cradick’s management experience includes being the second employee and Head of Genome Editing at CRISPR Therapeutics and the Chief Scientific Officer (CSO) at Excision BioTherapeutics, where he further expanded his IND, regulatory, IP, and Clinical Trial expertise
In 2000, TJ Cradick started in Zinc Finger design and selection at Sangamo Biosciences. This was followed by work on Zinc Finger Nucleases. At the University of Iowa, TJ designed the first nuclease that specifically cleaved the Hepatitis B virus and published the Surveyor gene editing essay. As faculty at Georgia Tech/Emory, TJ researched ZFNs, TAL effector nucleases (TALENs), and CRISPR for gene/genome editing for gene and cell therapy and co-authored many highly cited publications. At Georgia Tech, they started work on the hemoglobinopathies program with CRISPR Therapeutics that led to Casgevy.
In addition, TJ has extensive computational experience, having developed bioinformatics tools and websites for ZFN, TALEN & CRISPR target and off-target site nomination and co-authored manuscripts detailing bioinformatics web tools: ZFN-Site, PROGNOS (ZFNs and TALENs), SAPTA (TALENs) and COSMID (CRISPR specificity). TJ has worked extensively on computational methods for IND filings and clinical trials.
Over the years, TJ Cradick has provided due diligence, project management, intellectual property and research strategy and has assisted with IND and regulatory filings. TJ has also provided Gene Editing Specificity and Off-Target assay plans for Zinc Finger Nuclease (ZFN), TAL Effector Nuclease (TALEN), and many projects on CRISPR and newer technologies.
TJ Cradick, PhD, is a CRISPR and Gene Editing expert with > 22 years of research and management experience.
TJ Cradick’s management experience includes being the second employee and Head of Genome Editing at CRISPR Therapeutics and the chief scientific officer (CSO) at Excision BioTherapeutics, where he further expanded his IND, regulatory, IP, and Clinical Trial expertise.
In 2000, TJ Cradick started in Zinc Finger design and selection at Sangamo Biosciences. This was followed by work on Zinc Finger Nucleases. At the University of Iowa, TJ designed the first nuclease that specifically cleaved the Hepatitis B virus and published the Surveyor gene editing essay. As faculty at Georgia Tech/Emory, he researched ZFNs, TAL effector nucleases (TALENs), and CRISPR for gene/genome editing for gene and cell therapy. He co-authored many highly cited publications. At Georgia Tech, we started work on the hemoglobinopathies program with CRISPR Thereapeutics that led to Casgevy.
In addition, TJ has extensive computational experience, having developed bioinformatics tools and websites for ZFN, TALEN & CRISPR target and off-target site nomination and co-authored manuscripts detailing bioinformatics web tools: ZFN-Site, PROGNOS (ZFNs and TALENs), SAPTA (TALENs) and COSMID (CRISPR specificity). TJ has worked extensively on computational methods for IND filings and clinical trials.
Over the years, TJ Cradick has provided due diligence, project management, intellectual property and research strategy and has assisted with IND and regulatory filings. TJ has also provided Gene Editing Specificity and Off-Target assay plans for Zinc Finger Nuclease (ZFN), TAL Effector Nuclease (TALEN), and many projects on CRISPR and newer technologies.
TJ Cradick, PhD, is a CRISPR and Gene Editing expert with > 22 years of research and management experience.
TJ Cradick’s management experience includes being the second employee and Head of Genome Editing at CRISPR Therapeutics and the chief scientific officer (CSO) at Excision BioTherapeutics, where he further expanded his IND, regulatory, IP, and Clinical Trial expertise.
In 2000, TJ Cradick started in Zinc Finger design and selection at Sangamo Biosciences. This was followed by work on Zinc Finger Nucleases. At the University of Iowa, TJ designed the first nuclease that specifically cleaved the Hepatitis B virus and published the Surveyor gene editing essay. As faculty at Georgia Tech/Emory, he researched ZFNs, TAL effector nucleases (TALENs), and CRISPR for gene/genome editing for gene and cell therapy. He co-authored many highly cited publications. At Georgia Tech, we started work on the hemoglobinopathies program with CRISPR Thereapeutics that led to Casgevy.
In addition, TJ has extensive computational experience, having developed bioinformatics tools and websites for ZFN, TALEN & CRISPR target and off-target site nomination and co-authored manuscripts detailing bioinformatics web tools: ZFN-Site, PROGNOS (ZFNs and TALENs), SAPTA (TALENs) and COSMID (CRISPR specificity). TJ has worked extensively on computational methods for IND filings and clinical trials.
Over the years, TJ Cradick has provided due diligence, project management, intellectual property and research strategy and has assisted with IND and regulatory filings. TJ has also provided Gene Editing Specificity and Off-Target assay plans for Zinc Finger Nuclease (ZFN), TAL Effector Nuclease (TALEN), and many projects on CRISPR and newer technologies.